We are committed to delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections. We are developing Ibrexafungerp (formerly SCY-078), the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family, for the treatment of several serious fungal infections, including vulvovaginal candidiasis (VVC), invasive candidiasis, invasive aspergillosis and refractory invasive fungal infections.
Our team strives to save and improve patients' lives. We are committed to developing and delivering innovative therapies to address difficult-to-treat and often life-threatening infections, and to transforming treatment paradigms for patients worldwide.
More About Us
Our lead candidate, Ibrexafungerp (formerly SCY-078), currently in Phase 2 clinical development, is a novel and structurally distinct glucan synthase inhibitor. It is the first representative of a new triterpenoid antifungal family.
Our Science Our Pipeline
The innovation that drives our science and pipeline is a direct reflection of our leadership's passion for improving patients' lives. This leadership has a proven track record of drug development and commercialization, and deep antifungal expertise.
Leadership Board of Directors